Spots Global Cancer Trial Database for nab paclitaxel
Every month we try and update this database with for nab paclitaxel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial | NCT04872985 | Breast Cancer Hormone-recepto... | Pyrotinib Epirubicin Doxorubicin Hyd... Cyclophosphamid... Docetaxel Nab paclitaxel Placebo | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer | NCT06196788 | Pancreatic Canc... | Gemcitabine Nab paclitaxel | 18 Years - 80 Years | Fudan University | |
| Hepatic Arterial Infusion (HAI) of Abraxane | NCT00732836 | Liver Cancer Advanced Cancer... Solid Tumors | HAI Abraxane Hepatic Artery ... IV Abraxane | 18 Years - | M.D. Anderson Cancer Center | |
| Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | NCT02178436 | Acinar Cell Ade... Duct Cell Adeno... Stage IV Pancre... | gemcitabine hyd... Selinexor Pharmacological... Laboratory Biom... Nab paclitaxel | 19 Years - | Barbara Ann Karmanos Cancer Institute | |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | NCT04730219 | Muscle Invasive... Urothelial Carc... | Tislelizumab Nab paclitaxel | 18 Years - | Tianjin Medical University Second Hospital | |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | NCT04498689 | Metastatic Panc... | Camrelizumab Nab paclitaxel Gemcitabine Inj... | 18 Years - 75 Years | Fudan University | |
| Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | NCT05298020 | Advanced Pancre... | Envafolimab Endostar Nab paclitaxel Gemcitabine | 18 Years - | The Affiliated Hospital of Xuzhou Medical University | |
| Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | NCT05800340 | Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski... | Toripalimab Nab paclitaxel Pemetrexed Carboplatin | 18 Years - | Guangdong Provincial People's Hospital | |
| Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | NCT05044871 | Ovarian Cancer | Pamiparib Bevacizumab Tislelizumab Nab paclitaxel Bevacizumab + N... | 18 Years - | Tongji Hospital | |
| A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. | NCT05493995 | Pancreatic Neop... | Penpulimab Anlotinib Nab paclitaxel Gemcitabine | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis | NCT04000906 | Peritoneal Carc... | Nab paclitaxel Cisplatin | 18 Years - | University Hospital, Geneva | |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | NCT04498689 | Metastatic Panc... | Camrelizumab Nab paclitaxel Gemcitabine Inj... | 18 Years - 75 Years | Fudan University | |
| A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer | NCT05026905 | Phase II, Open-... | Gemcitabine 100... Nab paclitaxel S1 leucovorin Oxaliplatin | 20 Years - | National Health Research Institutes, Taiwan | |
| Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | NCT05800340 | Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski... | Toripalimab Nab paclitaxel Pemetrexed Carboplatin | 18 Years - | Guangdong Provincial People's Hospital | |
| A Study for the Neoadjuvant Treatment of Breast Cancer | NCT05420454 | Breast Cancer | Docetaxel Carboplatin Trastuzumab Pertuzumab Nab paclitaxel Epirubicin Cyclophosphamid... Docetaxel Epirubicin Cyclophosphamid... Nab paclitaxel | 18 Years - | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | NCT05251038 | Pancreatic Canc... Unresectable Pa... Metastatic Panc... KRAS P.G12C | Sotorasib Liposomal Irino... 5 Fluorouracil ... Leucovorin (LV) Gemcitabine (GE... Nab paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | NCT04676997 | Triple Negative... | Camrelizumab Nab paclitaxel Epirubicin Cyclophosphamid... | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma | NCT05687357 | Gastric Cancer Gastroesophagea... | Tislelizumab S-1 Oxaliplatin Nab paclitaxel Radiation | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | NCT05497778 | Pancreas Cancer | Gemcitabine Nab paclitaxel IM156 | 18 Years - | M.D. Anderson Cancer Center | |
| Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer | NCT05634564 | Pancreatic Carc... | Tislelizumab Gemcitabine Nab paclitaxel Hypofractionate... | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer | NCT06289062 | Cervical Cancer Neoadjuvant Che... Fertility Prese... | Camrelizumab Cisplatin Nab paclitaxel biopsy | 18 Years - 45 Years | Tongji Hospital | |
| LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer | NCT06387628 | TNBC - Triple-N... | LM-108 Toripalimab Eribulin Nab paclitaxel | 18 Years - 75 Years | Fudan University | |
| Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. | NCT04652206 | Metastatic Panc... Locally Advance... Inoperable Dise... Localized Pancr... | SCO-101 Gemcitabine Nab paclitaxel | 18 Years - | Scandion Oncology A/S | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC | NCT05244213 | Non-small Cell ... EGFR Activating... | Sintilimab Carboplatin Nab paclitaxel | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | NCT05327582 | Pancreatic Canc... Biliary Tract C... | Durvalumab Lenvatinib Nab paclitaxel | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | NCT05451043 | Pancreatic Canc... Hepatocellular ... Biliary Tract C... Cholangiocarcin... | Durvalumab Gemcitabine Nab paclitaxel Tremelimumab Propranolol Cisplatin | 18 Years - | AHS Cancer Control Alberta | |
| Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | NCT04543071 | Pancreatic Canc... Adenocarcinoma ... Adenocarcinoma | Motixafortide Cemiplimab Gemcitabine Nab paclitaxel | 18 Years - | Columbia University | |
| Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer | NCT05493501 | NSCLC | Aumolertinib mo... Osimertinib mon... Pemetrexed Cisplatin Carboplatin Paclitaxel Nab paclitaxel Gemcitabine | 18 Years - | EQRx International, Inc. | |
| APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | NCT04643405 | Advanced Pancre... | APG-1387 for In... Gemcitabine Nab paclitaxel | 18 Years - | Ascentage Pharma Group Inc. | |
| Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | NCT04047862 | Locally Advance... | Ociperlimab Tislelizumab Pemetrexed Paclitaxel Nab paclitaxel Carboplatin Cisplatin Etoposide 5fluorouracil Oxaliplatin Capecitabine | 18 Years - | BeiGene | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC | NCT04153734 | Locally Advance... | Pembrolizumab Cis Platinum Carboplatin Pemetrexed nab paclitaxel | - | Kobe Minimally Invasive Cancer Center | |
| A Study of Chemoradiation in Combination With Tislelizumab as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | NCT05919030 | Esophageal Squa... | Intensity-modul... Tislelizumab Cisplatin Nab paclitaxel | 18 Years - | Renmin Hospital of Wuhan University | |
| AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer | NCT06080854 | Pancreatic Carc... | Toripalimab Gemcitabine Nab paclitaxel SBRT | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | NCT05227664 | Metastatic Trip... Locally Advance... | AK117 AK112 Nab paclitaxel paclitaxel | 18 Years - 75 Years | Akeso | |
| Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | NCT05800587 | Lung Cancer Small-cell Lung... Non Small Cell ... | Carboplatin Pemetrexed Paclitaxel Nab paclitaxel Docetaxel Gemcitabine Etoposide Irinotecan Topotecan Lurbinectedin | 18 Years - | Fox Chase Cancer Center | |
| Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma | NCT05687357 | Gastric Cancer Gastroesophagea... | Tislelizumab S-1 Oxaliplatin Nab paclitaxel Radiation | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | NCT03169738 | Non-small Cell ... | avelumab Bevacizumab Capecitabine Cisplatin cyclophosphamid... 5-Fluorouracil ... fulvestrant leucovorin nab paclitaxel nivolumab Lovaza Oxaliplatin Stereotactic Bo... ALT-803 ETBX-011 ETBX-021 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK | 18 Years - | ImmunityBio, Inc. | |
| Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | NCT04548440 | Esophageal Squa... | Sintilimab Nab paclitaxel Cisplatin | 18 Years - | Sun Yat-sen University | |
| Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | NCT04548440 | Esophageal Squa... | Sintilimab Nab paclitaxel Cisplatin | 18 Years - | Sun Yat-sen University | |
| Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | NCT05821556 | Adenocarcinoma ... | Valproic acid Simvastatin 20m... Gemcitabine 100... Nab paclitaxel Cisplatin Capecitabine | 18 Years - | National Cancer Institute, Naples | |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | NCT03169738 | Non-small Cell ... | avelumab Bevacizumab Capecitabine Cisplatin cyclophosphamid... 5-Fluorouracil ... fulvestrant leucovorin nab paclitaxel nivolumab Lovaza Oxaliplatin Stereotactic Bo... ALT-803 ETBX-011 ETBX-021 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK | 18 Years - | ImmunityBio, Inc. | |
| IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer | NCT01830244 | Breast Cancer | Nab-Paclitaxel | 18 Years - | Barwon Health | |
| Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer | NCT04135781 | Stomach Cancer | nab paclitaxel Tegafur Oxaliplatin Capecitabine | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors | NCT05699811 | Locally Advance... | MSC-IFNα Nab paclitaxel Cyclophosphamid... Anti-PD-1 monoc... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | NCT05800340 | Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski... | Toripalimab Nab paclitaxel Pemetrexed Carboplatin | 18 Years - | Guangdong Provincial People's Hospital | |
| Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates | NCT02723331 | Pancreatic Canc... Pancreatic Aden... Pancreas Ductal... | Nab paclitaxel Gemcitabine | 18 Years - 101 Years | University of Colorado, Denver | |
| Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | NCT03668418 | Liver Cancer Pancreatic Canc... Gastric Cancer Esophageal Canc... Colo-rectal Can... Gall Bladder Ca... Biliary Tract C... | Fluorouracil Lederfolin Oxaliplatin Irinotecan Docetaxel Cisplatin Epirubicin Gemcitabine Nab paclitaxel | 18 Years - | University of Pisa | |
| Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC | NCT04153734 | Locally Advance... | Pembrolizumab Cis Platinum Carboplatin Pemetrexed nab paclitaxel | - | Kobe Minimally Invasive Cancer Center | |
| Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | NCT05047991 | Pancreatic Canc... Pancreatic Canc... | Irinotecan Lipo... Fluorouracil Leucovorin Oxaliplatin Nab paclitaxel Gemcitabine | 18 Years - 70 Years | CSPC Ouyi Pharmaceutical Co., Ltd. | |
| A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | NCT06041035 | Solid Tumor | QLS31905 Nab paclitaxel Gemcitabine Oxaliplatin Capecitabine Cisplatin | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | NCT04548440 | Esophageal Squa... | Sintilimab Nab paclitaxel Cisplatin | 18 Years - | Sun Yat-sen University | |
| Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer | NCT00629499 | Breast Cancer | nab paclitaxel Cyclophosphamid... Trastuzumab | 18 Years - | SCRI Development Innovations, LLC | |
| Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | NCT05825066 | Pancreas Adenoc... Borderline Rese... Locally Advance... | Nab paclitaxel Gemcitabine Radiological As... mFOLFIRINOX | 18 Years - | Wake Forest University Health Sciences | |
| Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer | NCT04827953 | Pancreatic Duct... | Gemcitabine Nab paclitaxel NLM-001 Zalifrelimab | 18 Years - 90 Years | Nelum Corp | |
| Hepatic Arterial Infusion (HAI) of Abraxane | NCT00732836 | Liver Cancer Advanced Cancer... Solid Tumors | HAI Abraxane Hepatic Artery ... IV Abraxane | 18 Years - | M.D. Anderson Cancer Center | |
| Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer | NCT04902261 | Recurrent Pancr... | Tislelizumab Nab paclitaxel Gemcitabine | 18 Years - | Changhai Hospital | |
| Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer | NCT00193206 | Breast Cancer | Gemcitabine Epirubicin Albumin-bound P... | 18 Years - | SCRI Development Innovations, LLC | |
| Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer | NCT05251766 | Breast Cancer Chemotherapy Ef... | Nab paclitaxel Docetaxel | 18 Years - 80 Years | Zhejiang Provincial People's Hospital | |
| CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence | NCT06037980 | Biliary Tract C... Cholangiocarcin... | Gemcitabine Nab paclitaxel Cisplatin Curative Surger... Capecitabine | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | NCT03169777 | Colorectal Canc... | avelumab bevacizumab capecitabine cetuximab Cyclophosphamid... 5-Fluorouracil ... fulvestrant leucovorin nab paclitaxel nivolumab Lovaza oxaliplatin Stereotactic Bo... ALT-803 ETBX-011 ETBX-021 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK | 18 Years - | ImmunityBio, Inc. | |
| Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC | NCT06288373 | Cervical Cancer Locally Advance... Concurrent Chem... Neoadjuvant Che... | Camrelizumab Cisplatin Nab paclitaxel Radical surgery external beam r... Cisplatin | 18 Years - 70 Years | Tongji Hospital | |
| Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck | NCT06016413 | Head and Neck S... | Nab paclitaxel Carboplatin adelbelimumab | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | NCT05582499 | Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC | 18 Years - 70 Years | Fudan University | |
| A Study for the Adjuvant Treatment of Breast Cancer | NCT05420467 | Breast Cancer | Docetaxel Carboplatin Trastuzumab Pertuzumab Nab paclitaxel Epirubicin Cyclophosphamid... Docetaxel Epirubicin Cyclophosphamid... Nab paclitaxel Cyclophosphamid... | 18 Years - | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | NCT03377491 | Pancreas Adenoc... | NovoTTF-200T Gemcitabine nab paclitaxel | 18 Years - | NovoCure Ltd. | |
| A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | NCT06041035 | Solid Tumor | QLS31905 Nab paclitaxel Gemcitabine Oxaliplatin Capecitabine Cisplatin | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. | NCT04835064 | Pancreatic Aden... | Nab paclitaxel Gemcitabine mFOLFIRINOX | 18 Years - 75 Years | Fudan University | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| Newly Emerging Immunotherapy for Pancreatic Cancer Treatment | NCT06370754 | Pancreatic Canc... | JS001 JS004 JS007 JS015 Irinotecan Lipo... 5-Fluorouracil ... Leucovorin (LV) Nab paclitaxel Gemcitabine | 18 Years - 75 Years | Fudan University | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery | NCT06209294 | Neoadjuvant Imm... Cervical Cancer Fertility-spari... | AK104 Carboplatin Nab paclitaxel | 18 Years - 45 Years | Fudan University | |
| Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck | NCT06016413 | Head and Neck S... | Nab paclitaxel Carboplatin adelbelimumab | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence | NCT06037980 | Biliary Tract C... Cholangiocarcin... | Gemcitabine Nab paclitaxel Cisplatin Curative Surger... Capecitabine | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer | NCT06018883 | Metastatic Panc... | Ascorbate Nab paclitaxel Gemcitabine | 18 Years - 80 Years | Fudan University | |
| Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | NCT03138889 | Non-Small Cell ... | NKTR-214 Pembrolizumab NKTR-214 NKTR-214 Cisplatin Carboplatin Nab paclitaxel Paclitaxel Pemetrexed Atezolizumab | 18 Years - | Nektar Therapeutics | |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03797443 | Metastatic Panc... | Ascorbic Acid nab paclitaxel Cisplatin Gemcitabine | 18 Years - | Piedmont Cancer Institute | |
| Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer | NCT04267549 | Gastric Cancer ... | sintilimab apatinib S1 Nab paclitaxel | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
